- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04022980
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Brookline, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- UNC Hospitals, The University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas - MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to participate in this study:
- Written informed consent and HIPAA authorization for release of personal health information of subject or subject's legally authorized representative.
- Age ≥ 65 years at the time of consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 within 14 days prior to day 1 of treatment
- Histological or cytological confirmation of PCNSL, CD20 positive by immunohistochemistry
- Received at least 2 cycles of high-dose methotrexate (HD-MTX) containing induction chemotherapy per institutional standard (R-MPV preferred; see Appendix VI ) without evidence of progressive disease. HD-MTX is typically defined as a MTX dose of at least 3.0 g/m^2.
- Recovered from all reversible acute toxic effects of prior therapy (other than alopecia) to ≤ Grade 1 or baseline)
- Measurable disease at the time of diagnosis (i.e. prior to pre-study HD-MTX containing induction chemotherapy) including lesions that can be accurately measured in 2 dimensions by CT or MRI of brain and with a greatest transverse diameter of ≥ 1 cm. The following disease assessments must have been obtained prior to initiation of pre-study HD-MTX containing induction chemotherapy: MRI of the brain with contrast (and spine with contrast if indicated)
- Deemed poor candidate for whole brain irradiation (WBI) or autologous stem cell transplant (ASCT) due to advanced age, ECOG performance status of 2, or in the opinion of the treating physician, subject would not tolerate the administration of WBI or ASCT for other reasons
- Life expectancy of at least 3 months
Demonstrate adequate organ function as defined below (all screening labs to be obtained within 14 days prior to day 1 of treatment):
- Absolute Neutrophil Count (ANC) ≥ 1000K/mm3
- Platelet Count ≥ 75 K/mm3
- Hemoglobin (Hgb) ≥ 8 g/dL
- Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 cc/minute as measured by a 24-hour urine collection or estimated by the Cockcroft and Gault formula
- Bilirubin ≤ 1.5 x upper limit of normal (ULN) (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0 x ULN)
- Aspartate aminotransferase (AST) ≤ 3 x ULN
- Alanine aminotransferase (ALT) ≤ 3 x ULN
Note: since subjects are not enrolled until study treatment is initiated, any labs drawn prior to initiating study treatment on Cycle 1 Day 1 need to meet eligibility criteria since the subject will still be in screening at the time of the lab draw.
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 3 days prior to day 1 of treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause).
- FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of <1% per year when used consistently and correctly) from the time of informed consent until 5 months after treatment discontinuation. Contraceptive methods with low user dependency are preferable but not required. (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf)
- As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study.
Exclusion Criteria:
Subjects must not meet any of the following criteria:
- Documented or suspected ophthalmologic involvement at the time of enrollment as determined by the investigator. Subjects with ophthalmologic involvement prior to or during pre-study induction are allowed if there is no evidence of ophthalmologic involvement prior to enrollment as determined by the investigator.
- Any concurrent systemic involvement by lymphoma outside CNS or intraocular lymphoma without evidence of brain disease
- Any previous chemotherapy or radiation therapy for PCNSL except for treatment with a HD-MTX containing induction chemotherapy. Subjects treated with corticosteroids for PCNSL are allowed.
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
- Has a known additional malignancy within the past 5 years that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or carcinoma of the prostrate with a current PSA value of <0.5 ng/mL or other cancer for which subject has completed treatment, been disease-free for at least five years, and is considered by Sponsor-Investigator to be at <30% risk of relapse, or on hormonal therapy for a history of either prostate cancer or breast cancer, provided that there has been no evidence of disease progression during the previous three years.
- Treatment with any investigational drug (including drugs not FDA-approved for the indication for which they are given) within 28 days prior to day 1 of treatment
- Subjects with active, uncontrolled infections (subjects must be afebrile for >48 hours off systemic antibiotics).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
- Major surgery and/or radiotherapy within 14 days prior to initiation of study treatment
- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed at sites where mandated locally.
- Active infectious hepatitis, type B or C. Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) may be included if HBV DNA is undetectable.
- Subjects with active interstitial pneumonitis.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stage 1
Safety Run-In
|
HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
|
Experimental: Stage 2
Expansion Cohort
|
HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Nivolumab in Older Subjects
Time Frame: Until up to 6 subjects can be adequately assessed for DLT.
|
The primary endpoint for the Stage 1 phase of the study is dose-limiting toxicity which will be assessed for each Stage 1 subject using the DLT criteria
|
Until up to 6 subjects can be adequately assessed for DLT.
|
Efficacy of Nivolumab
Time Frame: 2 years
|
The primary endpoint for the Stage 1 phase of the study is the 2-year progression-free endpoint which will be determined for each subject as a binary variable indicating if they are alive and progression-free at 2 years (PFS2)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: 2 years
|
PFS is defined as the duration of time from enrollment to first occurrence of either progressive disease or death.
|
2 years
|
Overall Survival (OS)
Time Frame: 2 years
|
OS is defined as the duration from enrollment to the date of death from any cause.
|
2 years
|
Objective and Complete Response Rates
Time Frame: approx. 2 years
|
Objective response will be determined for each subject as a binary variable indicating if they have achieved a best overall response of CR or PR as determined by the International Criteria for PCNSL (IPCG).
Complete response will be determined for each subject as a binary variable indicating if they have achieved a best overall response of CR as determined by the International Criteria for PCNSL(IPCG).
|
approx. 2 years
|
Conversion Rate from Partial to Complete Response
Time Frame: approx. 2 years
|
Response conversion will be determined for each subject who achieve a best overall response of PR during induction therapy as a binary variable indicating if the subsequently achieve a best overall response of CR to nivolumab consolidation therapy.
|
approx. 2 years
|
Subset Analysis of 2 Year Progression Free Survival
Time Frame: 2 years
|
A subset analysis of the primary population will be performed on those members of the evaluable population for the primary objective completing at least two cycles of nivolumab.
PFS is defined as the duration of time from enrollment to first occurrence of either progressive disease or death.
|
2 years
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: up to 30 days after last dose of Nivolumab
|
Adverse events will be collected for each subject using NCI CTCAE v5.0 criteria.
A binary variable will be determined for each subject indicating whether or not the subject experienced an AESI during treatment with nivolumab consolidation therapy, across any cycle nivolumab treatment administration.
|
up to 30 days after last dose of Nivolumab
|
Collaborators and Investigators
Investigators
- Principal Investigator: Steven Park, MD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00081673
- Pro00036735 (Other Identifier: Advarra IRB)
- LCI-HEM-PCNSL-RMPV-001 (Other Identifier: Atrium Heatlh)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Nervous System
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
National Cancer Institute (NCI)TerminatedCentral Nervous System Neoplasms | Brain Cancer | Neoplasms, Brain | Primary Brain Neoplasms | Cancer of the BrainUnited States
-
Stanford UniversityWithdrawnBrain and Nervous System
-
Tanta UniversityRecruiting
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
Hull University Teaching Hospitals NHS TrustUniversity of BathCompleted
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
University of PennsylvaniaCompleted
-
Chiang Mai UniversityYodying Punjasawadwong; Prangmalee Leucharussamee; Ananchanok Saringkarinkul; Patipan...CompletedBrain Neoplasms | Brain Cancer | Brain Tumor | Brain Metastases
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting